Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METROCREAM vs METROGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Rosacea (inflammatory papules and pustules),Topical treatment of bacterial vaginosis (off-label)
Topical treatment of inflammatory papules and pustules of rosacea,Treatment of bacterial vaginosis (off-label),Treatment of acne vulgaris (off-label)
Topical, apply a thin film to affected area once or twice daily.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Hepatic metabolism via oxidation and glucuronidation. Metronidazole is metabolized by CYP450 enzymes, primarily CYP2A6 and CYP3A4, forming metabolites such as hydroxy metronidazole and acetic acid metabolite.
Hepatic via glucuronidation and oxidation; metabolites excreted renally.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Metronidazole: <20% bound to plasma proteins.
Less than 20%; albumin.
Vd: ~0.6-0.7 L/kg, indicating distribution into total body water.
0.25-0.85 L/kg; extensive tissue distribution including CSF.
Topical: Systemic bioavailability approximately 0.1-1% of applied dose for metronidazole 1% cream.
Topical: minimal systemic absorption (2-4%); oral: 80-100%; intravenous: 100%.
No adjustment required for topical application.
No dose adjustment required for topical or intravaginal use; systemic absorption is minimal.
No adjustment required for topical application.
No dose adjustment required; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Safety and efficacy not established in pediatric patients under 18 years.
Topical 1% gel: apply twice daily for children ≥12 years; safety and efficacy for rosacea in children <12 not established.
No specific dose adjustment recommended; use caution due to potential skin atrophy.
No specific dose adjustment; use same dosing as adults; monitor for local adverse effects due to thinner skin.
None
No FDA black box warning.
Avoid contact with eyes. Use with caution in patients with blood dyscrasias or history of hypersensitivity to metronidazole. Prolonged use may result in overgrowth of non-susceptible organisms. Discontinue if irritation occurs.
Avoid unnecessary prolonged use; may cause peripheral neuropathy with chronic use; discontinue if neurological symptoms occur; photosensitivity reactions; avoid sun exposure.
Hypersensitivity to metronidazole or any component of the formulation.
Hypersensitivity to metronidazole or any component of the formulation; concurrent disulfiram use; history of alcoholic beverage consumption during therapy.
No significant food interactions due to negligible systemic absorption. However, alcohol consumption should be avoided during treatment and for at least 48 hours after discontinuing metronidazole, as trace systemic absorption may cause disulfiram-like reactions (nausea, vomiting, flushing, headache).
No significant food interactions specific to topical metronidazole; however, systemic metronidazole has alcohol interaction (disulfiram-like reaction), so patients should avoid alcohol while using topical formulation? Although topical absorption is minimal, caution is advised. No specific dietary restrictions.
Topical metronidazole (Metro Cream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, data do not suggest an increased risk of major malformations; however, use in first trimester is generally avoided due to theoretical risk. For topical application, systemic absorption is minimal (approximately 2%), and the drug is considered safe throughout pregnancy, with no known fetal risks.
Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neurodevelopmental risks unclear.
Minimal systemic absorption of metronidazole after topical application (approximately 2%) results in negligible transfer into breast milk. M/P ratio is not established for topical route. Use during breastfeeding is considered compatible; however, avoid application to breast area to prevent infant exposure.
Excreted in breast milk; M/P ratio ~1.0; American Academy of Pediatrics considers compatible; delay breastfeeding 12-24h after IV dose.
No dosage adjustment is necessary during pregnancy. Systemic absorption from topical application is minimal and pharmacokinetic changes in pregnancy do not warrant dose modification.
No dose adjustment required for topical METROGEL; systemic absorption negligible.
Metronidazole topical cream is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Avoid contact with eyes, mucous membranes, or open wounds. Use during pregnancy only if clearly needed (FDA category B). Warn patients that topical metronidazole may cause transient skin irritation or dryness; if severe, discontinue use. Combine with sunscreen and photoprotective measures due to potential photosensitivity. For rosacea, clinical improvement may take 3–4 weeks; adherence is critical. Do not use with concomitant oral metronidazole or disulfiram-like reactions due to minimal systemic absorption.
Metro Gel (metronidazole topical gel) is first-line for rosacea papules/pustules; avoid use in ocular rosacea as it can worsen symptoms. It is not effective for erythematotelangiectatic rosacea. For bacterial vaginosis, oral or intravaginal metronidazole is preferred; Metro Gel is not FDA-approved for vaginosis. In acne, it is less effective than topical antibiotics like clindamycin. Warn patients about rare metallic taste if gel is applied near lips.
Apply a thin layer to affected areas once or twice daily as directed.,Wash hands before and after application; avoid contact with eyes, mouth, and nostrils.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,May cause mild stinging, burning, or dryness; if severe, stop use and inform your physician.,Minimize sun exposure and use sunscreen daily as metronidazole may increase sun sensitivity.,Notify your doctor if you develop signs of allergic reaction: rash, itching, swelling, or trouble breathing.,Do not use more than prescribed; extended use may lead to bacterial resistance.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using.,Inform your doctor if you are taking oral metronidazole or have a history of blood disorders or neuropathy.
Apply a thin layer to affected areas once or twice daily as directed; avoid contact with eyes, mouth, and mucous membranes.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,Avoid sun exposure; use sunscreen and protective clothing as metronidazole may increase sensitivity to UV light.,Report any signs of allergic reaction (rash, itching, swelling) or worsening skin redness.,If accidental ingestion occurs, seek medical attention immediately; metronidazole can cause systemic side effects.,Do not use during pregnancy (especially first trimester) or while breastfeeding without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METROCREAM vs METROGEL, answered by our medical review team.
METROCREAM is a Antibiotic (Nitroimidazole) that works by Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.. METROGEL is a Antibiotic (Nitroimidazole) that works by Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METROCREAM and METROGEL depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METROCREAM is: Topical, apply a thin film to affected area once or twice daily.. The standard adult dose of METROGEL is: Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METROCREAM and METROGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METROCREAM is classified as Category C. Topical metronidazole (MetroCream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, da. METROGEL is classified as Category C. Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.